CIOMS FORM

SUSPECT ADVERSE REACTION REPORT

HN-Tolmar-TLM-2025-05931

## I. REACTION INFORMATION

| 1. PATIENT INITIALS (first, last) | 1a. COUNTRY | 2. DATE OF BIRTH | | | 2a. AGE Years | 3. SEX | 4-6 REACTION ONSET | | |
|---|---|---|---|---|---|---|---|---|---|
| | | Day | Month | Year | | | Day | Month | Year |
| MABA | HONDURAS | 24 | Nov | 1953 | 71 | Male | | Jan | 2025 |

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Head injury resulting from fall on public sidewalk while walking (Fall (10016173), Fall (10016173))
(24/Jul/2025 - ) - Recovering/Resolving
2) Head injury resulting from fall on public sidewalk while walking (Head injury (10019196), Head injury (10019196))
(24/Jul/2025 - ) - Recovering/Resolving
3) lipid profile elevation (Abnormal lipid profile (10000157), Lipids abnormal (10024588))
(/Jul/2025 - ) - Not Recovered/Not Resolved/Ongoing
4) pain in the occipital region of the head (Pain localised (10050483), Pain (10033371))
(24/Jul/2025 - ) - Recovering/Resolving

Cont..

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☐ PATIENT DIED
- ☑ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☑ OTHER MEDICALLY IMPORTANT CONDITION

## II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(Unknown)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)

1) (45 milligram(s), 1 in 6 Month)

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Prostate cancer [10060862 - Prostate cancer]

| 18. THERAPY DATE(S) (from/to) | 19. THERAPY DURATION |
|---|---|
| 1) (/May/2023 - Ongoing) | |

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

1)atorvastatin(ATORVASTATIN)(Tablet)

Cont..

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) ADVANCED PROSTATE CANCER (10085680, Advanced prostate cancer) (/Apr/2023 - ) (Continuing: Yes)

Cont..

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1-9702124900

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

| 24.REPORT NULLIFIED | 24b. MFR CONTROL NO. |
|---|---|
| ☐ YES ☐ NO | HN-Tolmar-TLM-2025-05931 |
| 24c. DATE RECEIVED BY MANUFACTURER: 18/Aug/2025 | 24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL |
| DATE OF THIS REPORT: 21/Aug/2025 | 25a. REPORT TYPE: ☑ INITIAL ☐ FOLLOWUP |

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

5) weight gain (Weight gain (10047896), Weight increased (10047899)(/Jan/2025 - ) - Not Recovered/Not Resolved/Ongoing)

Event Description :

This study report from Honduras was received by Adium via the "ASOFARMA A TU LADO" Patient Support Program (reference number: HN-ADIUM-HN-0327-20250818 (0) on 18-Aug-2025 from a consumer (non-healthcare professional) regarding an elderly 71-year-old male patient who experienced serious (life threatening) events of "Head injury resulting from fall on public sidewalk while walking" (fall) (medically significant) and (head injury) and non-serious events of "weight gain" (weight increased), ‘‘lipid profile elevation" (lipids abnormal), and "pain in the occipital region of the head" (pain) during Eligard (Leuprolide acetate) 45 mg therapy for prostate cancer. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 19-Aug-2025.

The patient's medical history was unknown. Current condition included prostate cancer, dyslipidaemia, umbilical hernia and obesity.

Concomitant medications included Atorvastatin.

On an unknown date in May-2023, the patient began receiving Eligard 45 mg, every 6 months, via subcutaneous route for prostate cancer (Lot numbers and Expiration dates were not provided).

On an unknown date in Jan-2025, the patient experienced weight gain.

On an unknown date in Jul-2025, the patient experienced an elevation in lipid profile.

On 24-Jul-2025, the patient suffered a fall while running errands, fell under his own weight, and hit his head on the sidewalk. He did not remember if he was unconscious. A neurological evaluation was performed four days later, and the CT scan reported normal findings, with no evidence of fracture, hematoma, or hemorrhage. He continued to have headaches in the occipital region, but they became milder. No further details were provided.

Corrective treatment included Atorvastatin for event lipids abnormal.

Relevant lab tests included:
On an unknown date: Weight: Weight gain (Ref. range not provided).
On an unknown date: Computerised tomogram: Normal (Ref. range not provided).
On an unknown date: Lipids: Elevated lipid profile (Ref. range not provided).

Action taken with Eligard in response to the event was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of fall, head injury and pain was recovering and of lipids abnormal and weight increased were not recovered.

The reporter assessed the seriousness of fall as serious (life threatening) and did not assess the seriousness of head injury, pain, lipids abnormal and weight increased.

The reporter assessed the causality of lipids abnormal, and weight increased in relationship to Eligard and Eligard unspecified device as related.

The reporter assessed the causality of fall, head injury and pain in relationship to Eligard and Eligard unspecified device as not related.

No further information is expected as consent to be contacted was not provided.

Listedness:
Fall>Eligard>Unlisted as per CCDS>07-Nov-2024
Fall>Eligard>Unlisted as per USPI>Feb-2025
Fall>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Fall>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Head injury>Eligard>Unlisted as per CCDS>07-Nov-2024
Head injury>Eligard>Unlisted as per USPI>Feb-2025
Head injury>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Head injury>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Pain>Eligard>listed as per CCDS>07-Nov-2024
Pain>Eligard>unlisted as per USPI>Feb-2025
Pain>Eligard unspecified device>unlisted as per USPI>Feb-2025
Pain>Eligard>listed as per Canadian monograph>O2-Apr-2025

Lipids abnormal>Eligard>Unlisted as per CCDS>07-Nov-2024
Lipids abnormal>Eligard>Unlisted as per USPI>Feb-2025
Lipids abnormal>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Lipids abnormal>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Continuation Sheet for CIOMS report

Weight increased>Eligard>listed as per CCDS>07-Nov-2024
Weight increased>Eligard>listed as per USPI>Feb-2025
Weight increased>Eligard unspecified device>listed as per USPI>Feb-2025
Weight increased>Eligard>listed as per Canadian monograph>O2-Apr-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This is regarding an elderly 71-year-old male patient who experienced fall, head injury(Head injury resulting from fall on public sidewalk while walking), pain (pain in the occipital region of the head), lipids abnormal (lipid profile elevation) and weight increased (weight gain), during Eligard (leuprolide acetate) 45 mg therapy for prostate cancer. Tolmar assessed the event fall and associated head injury as serious life threatening. Events weight increased, lipids abnormal and pain were assessed as non-serious since they did not meet the ICH seriousness criteria and are not IME events. The reported events fall, and associated head injury and pain were assessed as not related to Eligard (drug and device) considering accidental nature of reported event fall. Pain and head injury were secondary to fall hence assessed as not related. Event lipids abnormal, weight increased was assessed as not related to Eligard (Drug and device) as the events can be explained by underlying dyslipidaemia and obesity of the patient.

Additional Information (Continuation...)

Test Result (Code) / Result Unstructured Data (free text) :

1) Test Name: CT SCAN

Result Unstructured Data (free text) : Normal

Test Date:

2) Test Name: LIPID PROFILE

Result Unstructured Data (free text) : ELEVATED LIPID PROFILE

Test Date:

3) Test Name: WEIGHT

Result Unstructured Data (free text) : WEIGHT GAIN

Test Date:

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

| | | |
|---|---|---|
| 1) Drug | : | Eligard® (Leuprolide acetate) |
| Active Substance | : | 1) Leuprolide acetate |
| Drug Characterization | : | Suspect |
| Form of Admin | : | 1) Injection |
| Lot Number | : | 1) Unknown |
| Daily Dose | : | (45 milligram(s), 1 in 6 Month) |
| Route of Admin | : | 1) Subcutaneous |
| Indications | : | 1) Prostate cancer [10060862 - Prostate cancer] |
| Therapy Dates | : | 1) From : /May/2023 To :Continuing |
| Action(s) Taken With Drug | : | Dose not changed |

Causality

1) Head injury resulting from fall on public sidewalk while walking (Fall - 10016173, Fall - 10016173 )

| | | |
|---|---|---|
| Causality as per reporter | : | Not Related |
| Causality as per Mfr | : | Not Related |
| DeChallenge | : | Not applicable |
| ReChallenge | : | Not Applicable |

2) Head injury resulting from fall on public sidewalk while walking (Head injury - 10019196, Head injury - 10019196 )

| | | |
|---|---|---|
| Causality as per reporter | : | Not Related |
| Causality as per Mfr | : | Not Related |
| DeChallenge | : | Not applicable |
| ReChallenge | : | Not Applicable |

3) lipid profile elevation (Abnormal lipid profile - 10000157, Lipids abnormal - 10024588 )

| | | |
|---|---|---|
| Causality as per reporter | : | Related |
| Causality as per Mfr | : | Not Related |
| DeChallenge | : | Not applicable |
| ReChallenge | : | Not Applicable |

4) pain in the occipital region of the head (Pain localised - 10050483, Pain - 10033371 )

| | | |
|---|---|---|
| Causality as per reporter | : | Not Related |
| Causality as per Mfr | : | Not Related |

Continuation Sheet for CIOMS report

DeChallenge : Not applicable
ReChallenge : Not Applicable

5) weight gain (Weight gain - 10047896, Weight increased - 10047899 )
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Head injury resulting from fall on public sidewalk while walking
CORE UnLabeled
2) Head injury resulting from fall on public sidewalk while walking
CORE UnLabeled
3) lipid profile elevation
CORE UnLabeled
4) pain in the occipital region of the head
CORE Labeled
5) weight gain
CORE Labeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Action(s) Taken With Drug : Not applicable

Causality

1) Head injury resulting from fall on public sidewalk while walking (Fall - 10016173, Fall - 10016173 )
Causality as per reporter : Not Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) Head injury resulting from fall on public sidewalk while walking (Head injury - 10019196, Head injury - 10019196 )
Causality as per reporter : Not Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

3) lipid profile elevation (Abnormal lipid profile - 10000157, Lipids abnormal - 10024588 )
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

4) pain in the occipital region of the head (Pain localised - 10050483, Pain - 10033371 )
Causality as per reporter : Not Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

5) weight gain (Weight gain - 10047896, Weight increased - 10047899 )
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Head injury resulting from fall on public sidewalk while walking
CORE
2) Head injury resulting from fall on public sidewalk while walking
CORE
3) lipid profile elevation
CORE
4) pain in the occipital region of the head
CORE
5) weight gain
CORE

Continuation Sheet for CIOMS report

22.CONCOMITANT DRUG(S) (Continuation...)

| | | |
|---|---|---|
| 1). Drug | : | atorvastatin |
| Active Substance | : | 1) ATORVASTATIN |
| Form Strength | : | |
| Form of Admin | : | 1) Tablet |
| Daily Dose | : | 1) (20 milligram(s), 1 in 1 Day) |
| Indications | : | 1) MIXED DYSLIPIDAEMIA [10058108 - Dyslipidaemia] |

23. OTHER RELEVANT HISTORY (Continuation...)

2) MIXED DYSLIPIDAEMIA (10058108 , Dyslipidaemia) (Continuing : YES )

3) HERNIA UMBILICAL (10045458 , Umbilical hernia) (Continuing : YES )

4) OBESITY (10029883 , Obesity) (Continuing : YES )